The KDM5D Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KDM5D gene in the A-549 human lung adenocarcinoma epithelial cell line. This product offers a loss-of-function model for investigating KDM5D, a histone demethylase involved in transcriptional repression and spermatogenesis. The polyclonal population, generated via CRISPR/Cas9-mediated gene disruption, maintains edited cell heterogeneity for reliable experimental outcomes. Researchers can study KDM5D-dependent pathways, epigenetic regulation, and cancer biology.
The A-549 cell line, derived from a 58-year-old male lung adenocarcinoma, serves as an epithelial model for type II alveolar cells. Widely used in respiratory biology and oncology, A-549 cells are adherent and exhibit key lung epithelial markers, making them ideal for non-small cell lung cancer (NSCLC) research, metastasis studies, and drug discovery. The male origin ensures presence of the Y-chromosomal KDM5D, enabling investigation of sex-specific epigenetic mechanisms.
KDM5D is a histone H3K4 demethylase that removes di- and trimethyl marks (H3K4me2/me3) to repress transcription. It functions in chromatin remodeling during spermatogenesis and androgen receptor signaling. KDM5D is regulated by androgen receptor and testis-specific transcription factors, and it interacts with HDAC complexes and retinoblastoma protein (Rb) within transcriptional repression complexes. Its demethylase activity directly alters H3K4 methylation status, repressing target gene expression and potentially acting as a tumor suppressor.
In A-549 cells, KDM5D knockout enables dissection of its tumor-suppressive roles and epigenetic contributions in lung adenocarcinoma. As a Y-chromosome gene, KDM5D may influence sex-specific cancer disparities. Loss of KDM5D allows analysis of histone modification changes, gene expression shifts, and impacts on proliferation, apoptosis, and migration. This model is also valuable for examining crosstalk with HDAC/Rb pathways and testing epigenetic therapeutic strategies.
These polyclonal knockout cells are compatible with Western blot, RT-qPCR, immunofluorescence, and ChIP-qPCR to validate KDM5D disruption and assess H3K4 methylation. Functional assays including flow cytometry for apoptosis/cell cycle and migration/invasion assays can link KDM5D loss to cellular phenotypes. Applications span spermatogenesis, Y-chromosome gene studies, epigenetic regulation, androgen receptor signaling, and cancer biology. For further details, contact Ascent Research.
